The role of mean diffusivity (MD) as a predictive index of the response to chemotherapy in locally advanced breast cancer: a preliminary study

Iacconi, Chiara; Giannelli, Marco; Marini, Carolina; Cilotti, A; Moretti, Marco; Viacava, Paolo; Picano, Eugenia; Michelotti, Andrea; Caramella, Davide

doi:10.1007/s00330-009-1550-z

Cited by 77 publications

(48 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding is in agreement with other studies showing that changes in ADC can be found after only one cycle of NAC, with even a more pronounced increase after two cycles (8,10,33). This result is promising, because the implication is that ADC may be considered as a direct measure of treatment effects to chemotherapy.…”

Section: Discussionsupporting

confidence: 92%

Diffusion‐weighted and dynamic contrast‐enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients

Jensen¹,

Garzón²,

Heldahl³

et al. 2011

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Purpose: To use dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) MRI at 3 Tesla (T) for early evaluation of treatment effects in breast cancer patients undergoing neoadjuvant chemotherapy (NAC), and assess the reliability of DW-MRI.Materials and Methods: DW-and DCE-MRI acquisitions of 15 breast cancer patients were performed before and after one cycle of NAC. MRI tumor diameter and volume, apparent diffusion coefficient (ADC) and kinetic parameters (K trans , v e ) were derived. The reliability of ADC before NAC was assessed. Changes in MRI parameters after NAC were analyzed, and logistic regression analysis was used to find the best predictors for pathologic response. Results:The reliability for ADC values was high, with intraclass correlation coefficient of 0.84 (P ¼ 0.001). After one cycle of NAC, MRI tumor diameter (8%, P ¼ 0.005) and tumor volume (30%, P ¼ 0.008) was reduced for all patients, while ADC mean values increased (0.12 mm 2 /s, P ¼ 0.008). The best predictor for treatment response was a change in MRI tumor diameter with mean error rate of 0.167 (13% for responders, 5% for nonresponders, P ¼ 0.291).Conclusion: Changes in MRI derived tumor diameter and ADC after only one cycle of NAC could provide a valuable tool for early evaluation of treatment effects in breast cancer patients.

show abstract

Section: Discussionsupporting

confidence: 92%

Diffusion‐weighted and dynamic contrast‐enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients

Jensen¹,

Garzón²,

Heldahl³

et al. 2011

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…This study showed that for breast cancer patients undergoing neoadjuvant docetaxel/doxorubicin therapy, pretreatment tumor ADC was significantly lower in responders (1.04 × 10 −3 mm 2 /second), defined as patients with greater than 65% reduction in tumor volume after therapy, than in nonresponders (1.30 × 10 −3 mm 2 /second). A similar relationship between pretreatment tumor ADC and tumor volume change was also found by Iacconi et al (10). However, other studies have found no correlation between pretreatment tumor ADC and final tumor volume change or pathologic complete response (4,13,24).…”

Section: Discussionsupporting

confidence: 86%

High-Resolution Diffusion-Weighted Imaging for Monitoring Breast Cancer Treatment Response

Wilmes¹,

McLaughlin²,

Newitt³

et al. 2013

Academic Radiology

View full text Add to dashboard Cite

Rationale and Objectives The aim of this work was to compare a high-resolution diffusion-weighted imaging (HR-DWI) acquisition (voxel size = 4.8 mm3) to a standard diffusion-weighted imaging (STD-DWI) acquisition (voxel size = 29.3 mm3) for monitoring neoadjuvant therapy-induced changes in breast tumors. Materials and Methods Nine women with locally advanced breast cancer were imaged with both HR-DWI and STD-DWI before and after 3 weeks (early treatment) of neoadjuvant taxane-based treatment. Tumor apparent diffusion coefficient (ADC) metrics (mean and histogram percentiles) from both DWI methods were calculated, and their relationship to tumor volume change after 12 weeks of treatment (posttreatment) measured by dynamic contrast enhanced magnetic resonance imaging was evaluated with a Spearman’s rank correlation. Results The HR-DWI pretreatment 15th percentile tumor ADC (P = .03) and early treatment 15th, 25th, and 50th percentile tumor ADCs (P = .008, .010, .04, respectively) were significantly lower than the corresponding STD-DWI percentile ADCs. The mean tumor HR-ADC was significantly lower than STD-ADC at the early treatment time point (P = .02), but not at the pretreatment time point (P = .07). A significant early treatment increase in tumor ADC was found with both methods (P < .05). Correlations between HR-DWI tumor ADC and posttreatment tumor volume change were higher than the STD-DWI correlations at both time points and the lower percentile ADCs had the strongest correlations. Conclusion These initial results suggest that the HR-DWI technique has potential for improving characterization of low tumor ADC values over STD-DWI and that HR-DWI may be of value in evaluating tumor change with treatment.

show abstract

“…However, no consensus has been reached regarding the value of pretreatment ADC to predict the response to NAC. [17][18][19][20][21][22][23] It is also unclear whether this would be influenced by the tumor phenotype.…”

Section: Introductionmentioning

confidence: 97%

Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer

Bufi

Belli

Costantini

et al. 2015

Clinical Breast Cancer

View full text Add to dashboard Cite

The role of mean diffusivity (MD) as a predictive index of the response to chemotherapy in locally advanced breast cancer: a preliminary study

Cited by 77 publications

References 26 publications

Diffusion‐weighted and dynamic contrast‐enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients

Diffusion‐weighted and dynamic contrast‐enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients

High-Resolution Diffusion-Weighted Imaging for Monitoring Breast Cancer Treatment Response

Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer

Contact Info

Product

Resources

About